Indian Court Hands Novartis Setback In Gleevec Patent Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.
You may also be interested in...
Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings
Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations
Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings
Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations
Novartis Pitching New Product: A Fund For Tropical Disease Research
Novartis executive Paul Herrling has been on a whirlwind promotional tour the past few weeks. He's met with government leaders in China, Germany and the Netherlands, and academicians at Yale University, Columbia University and the New York Academy of Sciences. His goal: convincing them to support a new way to fund research on medicines for tuberculosis, dengue fever and other neglected tropical diseases